1 / 19

New concepts in HIV:

New concepts in HIV: HIV immunopathogenesis , treatment and vaccine strategies - report back from pre-conference. Nicolas Chomont VGTI-Florida. Christine Katlama: The HAART reality. HAART is not perfect! • Long term Toxicity • CD4/VL monitoring • Resistance • Cost.

illias
Download Presentation

New concepts in HIV:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida

  2. Christine Katlama: The HAART reality HAART is not perfect! • Long term Toxicity • CD4/VL monitoring • Resistance • Cost • New objectives for HIV therapy • Increased survival, stop progression, stop transmission • Decrease drug burden (number of ARV) to decrease toxicity and cost • Stop HAART (at least transitorily) • Functional cure / Eradication How can we measure the efficacy of interventions aimed at reducing the viral reservoirs?

  3. Doug Richman: Measuring HIV persistence Sensitivity and precision of current assays? S. Lewinand C. Rouzioux, AIDS 2011

  4. Optimal suppression of viral replication

  5. Mechanisms of HIV persistence Residual viremia in treated subjects: - Ongoing viral replication? - Viral production by long lived cells? Viral replication HAART Viral production

  6. Viral production: Identifying the source • Large variety of candidates: • CD4 T cells • Macrophages (Mario Stevenson) • Hematopoietic stem cells (C. Carter and K. Collins) • CNS • Others • We need to explore tissues (cell sorting and RNA/DNA quantification) • Can we match the sequence of the virus in plasma with the sequence in other compartments? • Intensification with drugs that penetrate tissues?

  7. Doug Richman: Mechanisms of HIV persistence • Evidences for the absence of ongoing viral replication • Little or no impact of treatment intensification • No evolution (resistance to ARV) • BUT • Buzon et al (Nat Med 2010) observed increased levels of 2-LTR circles upon Raltegravir intensification and reduced levels of activation • Yukl et al (AIDS 2010) observed an impact of HAART intensification in the ileum (unspliced HIV RNA)

  8. C. Katlama: Optimal suppression of viral replication • Nevirapine is associated with a higher rate of VL<1 copy/mL when compared with EFV or LPV (Bonora, J Med Virol 2009) • 40 virally suppressed patients with VL<1 copy/mL • Some of them still show high levels of immune activation (n=17) which are associated with: • A low Nadir CD4 • A low CD4/CD8 ratio (ongoing replication somewhere, bacterial translocation?) • Is residual viremia a good marker to monitor HIV persistence?

  9. HIV DNA in PBMCs Acute Chronic LTNP controllers Visconti S. Lewinand C. Rouzioux, AIDS 2011

  10. The VISCONTI patients Five out of 32 patients who received very early and prolonged antiretroviral therapy showed sustained immunovirological control for more than 6 years of treatment discontinuation. • 2 conditions: • Treat early (median 2.3 weeks) • Treat for long (median 5 years)

  11. HAART Circulating virus HAART Circulating virus Time

  12. RafickSekaly: Mechanisms of HIV persistence Viral replication T cell survival Proliferation

  13. Targeting the latent reservoir SAHA CD4 TCM cell survival Histone deacetylase inhibitors Suberoylanilide hydroxamic acid D. Margolis, D. Hazuda, C. VanLint, A. Savarino

  14. Targeting the cells: A role for PD-1 in HIV latency p24 (pg/ml) Time (d) The negative signal conferred by the PD-1/PD-L1 interaction inhibits viral production in primary CD4+T cells from viremicdonors PD-1 expression correlateswith the reservoirsize p=0,01 CD3/CD28 + IgG2 CD3/CD28 + PD-L1 NS

  15. Targeting the proliferative reservoir IL-15 CD4 T cell homeostatic proliferation IL-7 IL-7: Necessary for homeostatic renewal IL-15: Prompts cell maturation and viral replication

  16. Boosting immune responses: Vaccines • Correlates of control • T cells predict control (but not protection, Gary Nabel) • The magnitude and function of CD8 T cells are associated with control of the viral reservoir (Brigitte Autran). • NK cells (and their KIR receptors) are associated with viral control (Marcus Altfeld)

  17. Interventions for HIV Cure • Reduce residual replication/production: Optimize HAART (J. Martinez Picado, Stefano Vella) • Intensification • Drug penetration • Reduce immune activation (Steve Deeks) • Anti-inflammatory drugs • Reduce gut damage and /or microbial translocation • Anti CMV drugs • Target latent reservoirs • IL-7 (Eramune) or anti IL-7 • HDAC • Anti PD-1 • Gene Therapy (Jan Van Lunzen) • Immune control of reservoirs (Brigitte Autran) • IL-7 • HIV-specific IgG2 are associated with control in LTNP • NK cells C U R E

More Related